SHIRLEY, N.Y., Jan. 20, 2025 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company”) (TSXV: EVMT) is pleased to announce that the Company’s Board of Directors has approved the grant of 1,000,000 restricted stock units (RSUs) to William Garbarini in connection with his appointment as Chief Operating Officer, effective November 22, 2024.
The RSUs were granted under the Company’s Amended and Restated 2023 Equity Incentive Plan, will vest over a period of 24 months, and upon vesting will be settled in common shares of the Company. The RSUs and underlying common shares are subject to a four month and one day hold period pursuant to Canadian securities laws and the policies of the TSX Venture Exchange.
For more information please contact:
Mike Seckler
Chief Executive Officer
Tel: 1 (800) 760-6826
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
| Last Trade: | C$0.005 |
| Daily Volume: | 0 |
| Market Cap: | C$299K |
March 17, 2025 November 25, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
